PACB, US69404D1081

Pacific Biosciences stock gets mixed analyst target moves

Published on 11/20/2026 at 23:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pacific Biosciences stock drew mixed calls as Stephens and Barclays raised targets while UBS cut its view. The revisions span US$2 to US$2.70.

Analysts pull in different directions

  • Stephens and Barclays raised their Pacific Biosciences price targets while retaining different ratings.
  • UBS lowered its target and kept a Neutral rating, underscoring the split analyst view.
  • The latest revisions place published targets between US$2 and US$2.70.
PACB, US69404D1081, Illustration mit AI erstellt.

Analyst views on Pacific Biosciences of California diverged further on November 16, as Stephens and Barclays raised their price targets while UBS lowered its target. The changes were reported by Yahoo Finance in a report by Simply Wall St.

Mixed signals from analysts

Stephens lifted its target to US$2.50 from US$1.50 and retained an Overweight rating. Barclays raised its target to US$2 from US$1.25 but kept an Underweight rating, leaving a cautious stance despite the higher target.

UBS reduced its target to US$2.70 from US$3.05 and maintained a Neutral rating. Taken together, the revisions leave a wide range of published views and point to disagreement over PacBio's growth outlook and execution risks.

Latest trading context

Pacific Biosciences stock traded at 1.50 euros on Lang & Schwarz at 22:57 CET on Friday, November 20, 2026.

The analyst changes followed PacBio's third-quarter update earlier in November, when the company reported revenue of US$40.6 million and narrowed its 2026 revenue outlook to US$155 million-US$160 million. Those figures provide the operating backdrop for the competing target revisions.

Pacific Biosciences of California

  • Company: Pacific Biosciences of California, Inc.
  • ISIN: US69404D1081
  • Ticker: PACB
  • Primary exchange: Nasdaq
  • Latest quote: 1.50 euros on Lang & Schwarz, November 20, 2026, 22:57 CET
  • Analyst target range: US$2 to US$2.70

The broader U.S. market backdrop is covered through the S&P 500.

More news and analyses on Pacific Biosciences stock

Disclaimer...
en | US69404D1081 | PACB | boerse | 70541200 | bgmi